Literature DB >> 29123445

Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Tomoo Kishaba1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common cause of chronic diffuse parenchymal disease of unknown cause. However, IPF patients sometimes develop acute exacerbation (AE), which is a life-threatening condition. The cause of AE of IPF remains unknown. The new criteria for AE of IPF have been proposed last year, wherein both idiopathic and triggered AE were proposed. Triggered AE includes infection, post-procedure and post-operation, drug toxicity, and aspiration. Therefore, detailed history taking is crucial. In this review, the definition, clinical symptoms, chest imaging, management, and prognosis for AE of IPF are described.

Entities:  

Keywords:  Acute exacerbation; idiopathic; idiopathic pulmonary fibrosis; new criteria; triggered

Year:  2017        PMID: 29123445      PMCID: PMC5665631          DOI: 10.5152/eurasianjmed.2017.17219

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  37 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

Authors:  Marco Mura; Maria A Porretta; Elena Bargagli; Gianluigi Sergiacomi; Maurizio Zompatori; Nicola Sverzellati; Amedeo Taglieri; Fabrizio Mezzasalma; Paola Rottoli; Cesare Saltini; Paola Rogliani
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

3.  Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Kensuke Kataoka; Hiroyuki Taniguchi; Yasuhiro Kondoh; Osamu Nishiyama; Tomoki Kimura; Toshiaki Matsuda; Toshiki Yokoyama; Koji Sakamoto; Masahiko Ando
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

Review 4.  Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.

Authors:  C P Atkins; Y K Loke; A M Wilson
Journal:  Respir Med       Date:  2013-11-19       Impact factor: 3.415

5.  Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic.

Authors:  Ryo Tachikawa; Keisuke Tomii; Hiroyuki Ueda; Kazuma Nagata; Shigeki Nanjo; Ayako Sakurai; Kyoko Otsuka; Reiko Kaji; Michio Hayashi; Nobuyuki Katakami; Yukihiro Imai
Journal:  Respiration       Date:  2011-09-06       Impact factor: 3.580

6.  The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material.

Authors:  Niall D Ferguson; Eddy Fan; Luigi Camporota; Massimo Antonelli; Antonio Anzueto; Richard Beale; Laurent Brochard; Roy Brower; Andrés Esteban; Luciano Gattinoni; Andrew Rhodes; Arthur S Slutsky; Jean-Louis Vincent; Gordon D Rubenfeld; B Taylor Thompson; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2012-08-25       Impact factor: 17.440

7.  Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival.

Authors:  Hiromitsu Sumikawa; Takeshi Johkoh; Thomas V Colby; Kazuya Ichikado; Moritaka Suga; Hiroyuki Taniguchi; Yasuhiro Kondoh; Takashi Ogura; Hiroaki Arakawa; Kiminori Fujimoto; Atsuo Inoue; Naoki Mihara; Osamu Honda; Noriyuki Tomiyama; Hironobu Nakamura; Nestor L Müller
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

8.  [Outcome of patients with acute exacerbation of idiopathic interstitial fibrosis (IPF) treated with sivelestat and the prognostic value of serum KL-6 and surfactant protein D].

Authors:  Mari Nakamura; Takashi Ogura; Naoki Miyazawa; Akihiro Tagawa; Satoko Kozawa; Yuji Watanuki; Hiroshi Takahashi
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2007-06

9.  Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Hiromi Tomioka; Hirohito Takata
Journal:  Respirol Case Rep       Date:  2017-01-12

10.  A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).

Authors:  Takekazu Iwata; Ichiro Yoshino; Shigetoshi Yoshida; Norihiko Ikeda; Masahiro Tsuboi; Yuji Asato; Nobuyuki Katakami; Kazuhiro Sakamoto; Yoshinori Yamashita; Jiro Okami; Tetsuya Mitsudomi; Motohiro Yamashita; Hiroshi Yokouchi; Kenichi Okubo; Morihito Okada; Mitsuhiro Takenoyama; Masayuki Chida; Keisuke Tomii; Motoki Matsuura; Arata Azuma; Tae Iwasawa; Kazuyoshi Kuwano; Shuji Sakai; Kenzo Hiroshima; Junya Fukuoka; Kenichi Yoshimura; Hirohito Tada; Kazuhiko Nakagawa; Yoichi Nakanishi
Journal:  Respir Res       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.